



Adult CIRB - Late Phase Emphasis Meeting Agenda

May 21, 2026

I New Study - Initial Review

S2507, A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/Acute Leukemia With Ambiguous Lineage (ALAL) with Persistent Measurable Residual Disease (MRD) (Version Date 03/25/26)

II Continuing Review

A092204, A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN2810)) versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer (Version Date 07/14/25)

III Continuing Review

EAA241, A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone versus Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) (Version Date 01/30/26)
